Maternal Human Milk Oligosaccharide Profile Modulates the Impact of an Intervention with Iron and Galacto-Oligosaccharides in Kenyan Infants.

There is little data on human milk oligosaccharide (HMO) composition in Sub-Saharan Africa. Iron fortificants adversely affect the infant gut microbiota, while co-provision of prebiotic galacto-oligosaccharides (GOS) mitigates most of the adverse effects. Whether variations in maternal HMO profile can influence the infant response to iron and/or GOS fortificants is unknown. The aim of this study was to determine HMO profiles and the secretor/non-secretor phenotype of lactating Kenyan mothers and investigate their effects on the maternal and infant gut microbiota, and on the infant response to a fortification intervention with 5 mg iron (2.5 mg as sodium iron ethylenediaminetetraacetate and 2.5 mg as ferrous fumarate) and 7.5 g GOS. We studied mother-infant pairs (n = 80) participating in a 4-month intervention trial in which the infants (aged 6.5-9.5 months) received daily a micronutrient powder without iron, with iron or with iron and GOS. We assessed: (1) maternal secretor status and HMO composition; (2) effects of secretor status on the maternal and infant gut microbiota in a cross-sectional analysis at baseline of the intervention trial; and (3) interactions between secretor status and intervention groups during the intervention trial on the infant gut microbiota, gut inflammation, iron status, growth and infectious morbidity. Secretor prevalence was 72% and HMOs differed between secretors and non-secretors and over time of lactation. Secretor status did not predict the baseline composition of the maternal and infant gut microbiota. There was a secretor-status-by-intervention-group interaction on Bifidobacterium (p = 0.021), Z-scores for length-for-age (p = 0.022) and weight-for-age (p = 0.018), and soluble transferrin receptor (p = 0.041). In the no iron group, longitudinal prevalence of diarrhea was higher among infants of non-secretors (23.8%) than of secretors (10.4%) (p = 0.001). In conclusion, HMO profile may modulate the infant gut microbiota response to fortificant iron; compared to infants of secretor mothers, infants of non-secretor mothers may be more vulnerable to the adverse effect of iron but also benefit more from the co-provision of GOS.

Galacto-Oligosaccharide/Polidextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy: A Randomized Clinical Trial.

BACKGROUND: Early nutrition affects the risk of atopy and infections through modifications of intestinal microbiota. The Prebiotics in the Prevention of Atopy (PIPA) study was a 24-month randomised, double-blind, placebo-controlled trial. It aimed to evaluate the effects of a galacto-oligosaccharide/polydextrose (GOS/PDX)-formula (PF) on atopic dermatitis (AD) and common infections in infants who were born to atopic parents and to investigate the relationship among early nutrition, gut microbiota and clinical outcomes. METHODS: A total of 201 and 199 infants were randomized to receive a PF and standard formula (SF), respectively; 140 infants remained on exclusive breastfeeding (BF). RESULTS: The cumulative incidence of AD and its intensity and duration were not statistically different among the three groups. The number of infants with at least one episode of respiratory infection (RI) and the mean number of episodes until 48 weeks of age were significantly lower in the PF group than in the SF group. The number of patients with recurrent RIs and incidence of wheezing lower RIs until 96 weeks were lower in the PF group than the SF group, but similar to the BF group. Bifidobacteria and Clostridium cluster I colonization increased over time in the PF group but decreased in the SF and BF groups. Bifidobacteria had a protective role in RIs, whereas Clostridium cluster I was associated with atopy protection. CONCLUSION: The early administration of PF protects against RIs and mediates a species-specific modulation of the intestinal microbiota. TRIAL REGISTRATION: clinicaltrial.gov Identifier: NCT02116452.

Rapid Identification and Assignation of the Active Ingredients in Fufang Banbianlian Injection Using HPLC-DAD-ESI-IT-TOF-MS.

Fufang Banbianlian Injection (FBI) is a well-known traditional Chinese medicine formula composed of three herbal medicines. However, the systematic investigation on its chemical components has not been reported yet. In this study, a high-performance liquid chromatography combined with diode-array detector, and coupled to an electrospray ionization with ion-trap time-of-flight mass spectrometry (HPLC-DAD-ESI-IT-TOF-MS) method, was established for the identification of chemical profile in FBI. Sixty-six major constituents (14 phenolic acids, 14 iridoids, 20 flavonoids, 2 benzylideneacetone compounds, 3 phenylethanoid glycosides, 1 coumarin, 1 lignan, 3 nucleosides, 1 amino acids, 1 monosaccharides, 2 oligosaccharides, 3 alduronic acids and citric acid) were identified or tentatively characterized by comparing their retention times and MS spectra with those of standards or literature data. Finally, all constituents were further assigned in the individual herbs (InHs), although some of them were from multiple InHs. As a result, 11 compounds were from Lobelia chinensis Lour, 33 compounds were from Scutellaria barbata D. Don and 38 compounds were from Hedyotis diffusa Willd. In conclusion, the developed HPLC-DAD-ESI-IT-TOF-MS method is a rapid and efficient technique for analysis of FBI sample, and could be a valuable method for the further study on the quality control of the FBI.

Effects of short-chain fructooligosaccharides (scFOS) and rearing temperature on growth performance and hepatic intermediary metabolism in gilthead sea bream (Sparus aurata) juveniles.

The effect of dietary short-chain fructooligosaccharides (scFOS) incorporation on growth, feed utilization, body composition, plasmatic metabolites and liver activity of key enzymes of lipogenic and amino acid catabolic pathways was evaluated in gilthead sea bream reared at 18 and 25 °C. Four practical diets containing plant ingredients and fish meal (50:50) as protein sources and supplemented with 0, 0.1, 0.25 and 0.5 % scFOS were fed to triplicate groups of fish for 8 weeks. Growth performance, feed efficiency and nitrogen retention were higher at 25 °C. In fish reared at 18 °C, there was a positive correlation between dietary scFOS concentration and growth. At 18 °C, liver glycogen was higher in fish fed the control diet, while at 25 °C it was higher in fish fed the 0.5 % scFOS diet. Plasma cholesterol LDL was lower in fish fed 0.25 % scFOS diet, and in fish reared at 18 °C plasma glucose was higher in fish fed the 0.1 % scFOS diet. Glucose 6-phosphate dehydrogenase, fatty acid synthetase and aspartate aminotransferase (ASAT) activities were higher in fish reared at 18 °C, whereas alanine aminotransferase activity was higher in fish reared at 25 °C. scFOS affected ASAT activity, which was lower in fish fed 0.25 % scFOS diet. Although, scFOS seemed to have no major effects on gilthead sea bream metabolism, the positive correlation between dietary prebiotic incorporation and growth at 18 °C indicates a beneficial effect of scFOS in fish reared at low temperatures.

Prebióticos en las fórmulas para lactantes. ¿Podemos modificar la respuesta inmune? / Prebiotics in infant formulae. Could we modify the immune response?

Introducción: La microflora intestinal de los lactantes amamantados tiene un papel primordial en la función intestinal y en el desarrollo del sistema inmune. Los oligosacáridos presentes en la leche materna estimulan selectivamente el crecimiento de Bifidobacterias y Lactobacilos en el intestino. En los últimos años se han realizado varios intentos para obtener una flora similar en lactantes alimentados con fórmulas infantiles. Una de las posibilidades para obtener este efecto es proporcionar nutrientes selectivos para esta microflora beneficiosa (prebióticos). Objetivo: Realizar una revisión de la evidencia científica disponible sobre la incorporación de prebióticos a los alimentos para lactantes y su posible influencia en la respuesta inmune. Material y métodos: Se realizó un amplia búsqueda bibliográfica con los siguientes términos de búsqueda: "prebióticos OR oligosacáridos OR microflora intestinal AND fórmula infantil AND resultados". Se hizo especial análisis de los estudios clínicos con fórmulas infantiles que incorporaran prebióticos. Resultados: Un prebiótico es una sustancia no absorbible en el intestino delgado y susceptible de fermentación por la flora colónica. El empleo de una mezcla determinada de galactooligosacáridos y fructooligosacáridos en una fórmula infantil aumenta el número de bifidobacterias de una forma dependiente de la dosis (el efecto máximo obtenido a una concentración de 0,8 g/dl) y reduce el número de gérmenes patógenos tanto en lactantes pretérminos como a término cuando se comparaban con lactantes que recibían una fórmula no suplementada. El efecto de los oligosacáridos sobre el metabolismo bacteriano se estudió midiendo la producción de ácidos grasos de cadena corta y el pH fecal. Estudios más recientes han mostrado beneficios clínicos de la incorporación de una mezcla de prebióticos a una fórmula infantil. En primer lugar, se ha visto una disminución en el riesgo de aparición de dermatitis atópica en lactantes de riesgo; en segundo lugar, una reducción en el número de episodios infecciosos, fundamentalmente intestinales e infecciones de vías respiratorias superiores en el primer año de vida. Puede especularse que los prebióticos pueden tener un papel importante en la prevención de la alergia y de las infecciones leves en el lactante (AU)

Introduction: The intestinal microflora of breast-fed infants is an important physiological factor in gut function and the development of the immune system. Human milk oligosaccharides have been shown to selectively stimulate the growth of Bifidobacteria and Lactobacilli in the intestine. In the last few years several attempts have been made to establish the presence of similar microbiota in formula-fed infants. One of the approaches to modify the balance of intestinal microflora is to supply the potentially helpful microbiota with selective nutrients (prebiotics). Goal: To review the current scientific evidence related to the addition of prebiotics to infant feeds and their possible role in the immune function. Material and methods: A bibliographic search with Mesh terms: Prebiotics OR oligosaccharides OR intestinal microflora AND infant formula AND results was performed. Special analysis was done on clinical studies. Results: Prebiotics are substances that are not absorbed through the small intestine and are fermented by colonic bacteria. A prebiotic mixture from galacto-oligosaccharides and fructo-oligosaccharides has been used to mimic the effect of human milk oligosaccharides. It has been demonstrated that such a mixture significantly increases the number of bifidobacteria in a dose-related way (maximum effect at 0.8 g/dl) and reduces the number of pathogens in term as well as in preterm infants when compared with a group of infants fed a non-supplemented formula. The effect of oligosaccharides on bacterial metabolism was studied by measuring short chain fatty acid production and fecal pH. More recent studies have been able to show clinical benefits with the use of a prebiotic mixture in infant formulas. Firstly, it has been shown to decrease the risk of developing atopic dermatitis in high risk infants; secondly a reduced incidence of intestinal as well as upper airway infections in the first year of life. It can be hypothesized that prebiotics might play an important role as a new concept in allergy and infection prevention in infants (AU)